Lerøy Seafood Group ASA LSG

Oslo Børs · Consumer Defensive · Packaged Foods

42.76 NOK −1.8% 2026-11-06

☆ Create a free account to watch Backtest this stock Compare Price history

Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.

Annual accounts for Lerøy Seafood Group

NOK million	2022	2023	2024	2025
Income statement
Revenue	26,641	30,853	31,124	34,362
EBITDA	5,715	4,637	4,923	2,969
Net income	2,907	273	2,673	366
Balance sheet
Equity	19,709	18,687	20,009	18,798
Total debt	9,193	10,965	13,423	12,891
Cash	3,305	4,323	3,197	2,519
Net debt	5,889	6,642	10,226	10,372
Ratios and per share
EBITDA margin	21.5%	15.0%	15.8%	8.6%
Profit margin	10.9%	0.9%	8.6%	1.1%
Return on equity	14.7%	1.5%	13.4%	1.9%
Earnings/share (NOK)	4.88	0.46	4.49	0.61
Book value/share (NOK)	33.10	31.38	33.60	31.57
Shares outstanding (M)	595	595	595	595

From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →

Quarterly figures from the reports

Beta

From the company's own reports: 49 reports read by AI, every figure checked against the report's page and arithmetic.

Revenue Q2 2026

12,169

NOK million

Operating profit Q2 2026

−321

NOK million

EPS Q2 2026

−0.34

NOK

One-off items found

in 49 reports

Source: the Q2 2026 report, page 29, published 2026-08-19.

Quarter	Revenue	Operating profit	Profit	EPS	Adj. EPS	Source
Q2 2026	12,169	−321	−202	−0.34	…	Q2 2026, p. 29
Q1 2026	3,808	541	288	0.84	…	Q1 2026, p. 26
Q4 2025	3,883	891	175	0.29	…	Q4 2025, p. 26
Q3 2025	39	870	449	−0.34	…	Q3 2025, p. 42
Q2 2025	16,769	53	125	0.75	…	Q2 2025, p. 42
Q1 2025	8	−755	−383	−0.64	…	Q1 2025, p. 26
Q4 2024	8,477	1,247	1,610	2.70	…	Q4 2024, p. 20
Q3 2024	7,889	−226	−56	0.62	…	Q3 2024, p. 19
Q2 2024	7,648	1,158	645	1.08	…	Q2 2024, p. 20
Q1 2024	7,110	847	474	0.80	…	Q1 2025, p. 26
Q4 2023	8,229	941	864	1.45	…	Q4 2023, p. 18
Q3 2023	8,001	−185	−366	−0.62	…	Q3 2023, p. 18

Amounts in NOK million, EPS in NOK. Each quarter as first reported, as a backtest would have seen it. Adjusted EPS (without one-off items) is shown once the one-off items have been checked against the companies' own adjusted figures.

One-off items in the reports

2026-06-30 Impairment loss line (positive amount, a gain in Q2 2026; excluded from operational EBIT): +22.9 NOK million (Q2 2026, p. 28)
2026-06-30 Litigation costs (excluded from operational EBIT): −6.8 NOK million (Q2 2026, p. 28)
2026-06-30 Production fee on slaughtered volume (tax related, excluded from operational EBIT): −44.1 NOK million (Q2 2026, p. 28)
2026-06-30 Change in unrealised internal margin (excluded from operational EBIT): −4.9 NOK million (Q2 2026, p. 28)
2026-06-30 Change in fair value adjustment on biological assets (excluded from operational EBIT): −862.6 NOK million (Q2 2026, p. 28)
2026-03-31 Change in unrealised internal margin (excluded from operational EBIT): −16.1 NOK million (Q1 2026, p. 25)
2026-03-31 Change in fair value adjustment on biological assets (excluded from operational EBIT): −299.4 NOK million (Q1 2026, p. 36)
2026-03-31 Change in fair value of onerous contracts (excluded from operational EBIT): +44.0 NOK million (Q1 2026, p. 36)

Found by AI and still being validated: hover for the report's own words.

Extracted by an AI model from the reports and can be wrong. Not investment advice.

Key figures

P/E	69.6
P/B	1.4
EV / EBITDA	12.1
Net debt / EBITDA	3.5
Return on equity	1.9%
Profit margin	1.1%
Beta 1Y	0.37
Revenue growth 1Y	+10.4%
Revenue CAGR 3Y	+8.9%
Earnings/share CAGR 3Y	−49.9%
ROE avg. 3Y	5.6%

Ratios use the latest annual report that was public 90 days after the year end.

Dividends per share (NOK)

2026	2.50
2025	2.50
2024	2.50
2023	2.50
2022	2.50

Not investment advice. Figures may contain errors from the data source.